Journal of Medical Economics最新文献

{"title":"Real-world all-cause healthcare resource utilization and costs among patients with interstitial cystitis/bladder pain syndrome in the United States.","authors":"Jaromir Mikl, Tiange Yu, Xin Zhao, Catherine Allende, Amie Devlin, Valentine Pascale, Roger Dmochowski","doi":"10.1080/13696998.2026.2713912","DOIUrl":"https://doi.org/10.1080/13696998.2026.2713912","url":null,"abstract":"<p><strong>Introduction: </strong>Interstitial cystitis/bladder pain syndrome (IC/BPS) is a persistent and heterogeneous condition diagnosed by exclusion, defined by a bladder-associated unpleasant sensation (e.g. pain, pressure, or discomfort), and affecting patients' quality of life. This real-world study aimed to describe all-cause healthcare resource utilization (HCRU) and costs associated with IC/BPS in the United States.</p><p><strong>Methods: </strong>This matched-cohort study compared patients with an IC/BPS diagnosis to those without using real-world claims from the Merative MarketScan Commercial and Medicare Supplemental Databases (Set B; January 1, 2016-June 30, 2025). The index date was the first IC/BPS diagnosis during the identification period (January 1, 2017-September 30, 2022). During the baseline and follow-up periods, all-cause HCRU and costs (i.e. billed expenses) were reported as means per patient per year (PPPY) and rate ratios (RR).</p><p><strong>Results: </strong>In the 1-year baseline period, the IC/BPS cohort demonstrated higher all-cause HCRU and costs across all categories compared with the control cohort. During the follow-up period, mean all-cause total visits were nearly 2-fold higher in the IC/BPS cohort than in the control cohort (21.78 vs. 10.94 PPPY; RR, 1.99; 95% CI, 1.95-2.04); mean all-cause total healthcare costs were also nearly 2-fold higher in the IC/BPS cohort than in the control cohort ($20,288 vs. $10,222 PPPY; RR, 1.98; 95% CI, 1.92-2.05).</p><p><strong>Limitations: </strong>This observational study of all-cause HCRU based on claims data provides insights rather than conclusions. Claims data rely on coded diagnoses and may lack information on disease severity, adherence, and indirect costs, introducing bias (e.g. diagnosis misclassification or residual confounding) and affecting the generalizability of results.</p><p><strong>Conclusions: </strong>This exploratory study demonstrated that the healthcare burden among patients diagnosed with IC/BPS remained substantial over time. These findings highlight the need for further research on cost drivers and management strategies to improve outcomes and reduce all-cause HCRU and costs among patients with IC/BPS.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"2135-2149"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148706874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indirect comparison of mRNA-1010 versus enhanced influenza vaccines in adults aged 65 years and older during the 2024-2025 US influenza season.","authors":"Keya Joshi, Aaron Situ, Darshan Mehta, Linwei Li, Chelsea Canan, John Youhanna, Jennifer M Radin, Deborah Rudin, Mihaela Georgieva, Nicolas Van de Velde","doi":"10.1080/13696998.2026.2706361","DOIUrl":"https://doi.org/10.1080/13696998.2026.2706361","url":null,"abstract":"<p><strong>Aims: </strong>Seasonal influenza continues to cause severe disease among older adults in the United States despite enhanced vaccine recommendations, driven by immunosenescence and vaccine mismatch with circulating influenza viruses. mRNA-based influenza vaccines (mRNA-1010), addressing some of these challenges, have been developed for this population. A previous trial found mRNA-1010 demonstrated superior immunogenicity compared to enhanced high-dose influenza vaccination. As no direct evidence exists comparing mRNA-1010 efficacy to currently available enhanced influenza vaccines (EVs), we aimed to indirectly compare the effectiveness of mRNA-1010 and licensed EVs against medically attended influenza infection among adults ≥65 years in the US.</p><p><strong>Materials and methods: </strong>We conducted an anchored indirect treatment comparison (ITC) using the Bucher method to estimate the relative vaccine effectiveness (rVE) of mRNA-1010 vs EV, with standard-dose egg-based influenza vaccine as the anchor, using individual patient-level data from adults ≥65 years from a real-world Optum claims-based analysis and the pivotal mRNA-1010-P304 clinical trial. Target trial emulation and inverse probability weighting (IPW) were implemented to address potential bias due to cross-population differences. Sensitivity analyses were conducted using alternative outcome definition, alternative weighting approaches and US trial sites only.</p><p><strong>Results: </strong>Assessments of post-IPW supported a comparable common anchor for the ITC. Among adults ≥65 years, the indirect rVE of mRNA-1010 vs. enhanced vaccines against medically attended influenza was 12.82% (95% CI: -36.91%, 44.49%). Sensitivity analyses also supported these findings.</p><p><strong>Limitations and conclusions: </strong>mRNA-1010, a new mRNA-based influenza vaccine, was shown to be comparable to currently licensed EVs among older adults ≥65 years against medically attended influenza outcomes. Consistency of findings across sensitivity analyses support the robustness of these results. Newer influenza vaccine modalities, including mRNA-based vaccines provide an additional comparable option to existing EVs to help further reduce severe influenza disease burden among older adults ≥65 years for whom enhanced vaccines are recommended.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"2046-2062"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148669385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world healthcare resource utilization and cost burden of COVID-19 in commercially insured adults at high-risk of severe disease in the US: a retrospective database analysis.","authors":"Tendai Mugwagwa, Benjamin A Abramoff, Siddharth Karanth, Tram Nham, Ravi K Goyal, Elizabeth Esterberg, Gurinder S Sidhu, Alon Yehoshua, Ruth Mokgokong","doi":"10.1080/13696998.2026.2725478","DOIUrl":"https://doi.org/10.1080/13696998.2026.2725478","url":null,"abstract":"<p><strong>Background and aim: </strong>High-risk patients with COVID-19 remained at elevated risk of severe outcomes in the Omicron era, even after receiving multiple vaccine doses. We report the Omicron-era healthcare resource utilization (HCRU) and cost burden of COVID-19 among commercially insured, oral antiviral therapy-eligible patients at high risk of severe disease.</p><p><strong>Methods: </strong>This retrospective analysis used the TriNetX Linked US database. Eligible commercially insured patients were aged ≥18 years, had a COVID-19 diagnosis between 1 July 2023 and 30 June 2024, and had ≥1 risk factor for severe COVID-19. All-cause and COVID-19-related HCRU and costs were assessed during acute (0-30 days from diagnosis) and post-acute (31 days until December 31, 2024) follow-up.</p><p><strong>Results: </strong>Of the 43,487 eligible patients, 56.2% were aged ≥50 years and 85.6% had 1-5 high-risk conditions. Patients were followed for a mean of 11.4 months following COVID-19 diagnosis (acute phase, 1.0 month; post-acute phase, 10.6 months). 13,499 patients (31.0%) received treatment for COVID-19. 9.8% of patients had ≥1 all-cause inpatient general ward admission, with a mean per-patient (PP) total cost of $14,715 (acute phase, $10,833 PP; post-acute phase, $14,403 PP). 1.3% of patients had an all-cause intensive care unit (ICU) admission, with a mean PP total cost of $75,371 (acute phase, $62,882 PP; post-acute phase, $71,666 PP). Among the small number of patients requiring mechanical ventilation in the ICU, mean all-cause PP costs were $135,677 PP overall (acute phase, $106,577 PP; post-acute phase, $130,309 PP). 28.4% of patients had ≥1 all-cause emergency department visit (mean total cost, $1,434 PP; acute phase, $842 PP; post-acute phase, $1,408 PP).</p><p><strong>Conclusions: </strong>During the Omicron era, HCRU and costs remained substantial and increased with disease severity among commercially insured patients at high risk of severe COVID-19. These findings are crucial to inform economic evaluations and payer decision‑making regarding COVID‑19 antiviral therapies.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"2267-2282"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148887724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cell and gene therapies in managed care: US payer insights on coverage and financial risk.","authors":"Elias C Pittos, Joe DePinto","doi":"10.1080/13696998.2026.2719325","DOIUrl":"https://doi.org/10.1080/13696998.2026.2719325","url":null,"abstract":"<p><strong>Aims: </strong>Cell and gene therapies (CGTs) are increasingly transforming the treatment of serious and life-threatening conditions, offering durable and, in some cases, potentially curative benefit. However, high upfront costs paired with the expectation for long-term value realization create misalignment with conventional managed care and reimbursement models. Although innovative payment and risk-sharing strategies have been proposed, adoption remains limited. Understanding how payers are navigating these challenges is increasingly critical as CGTs continue to transition into established standards of care.</p><p><strong>Methods: </strong>Sixty-minute, double-anonymized, semi-structured interviews were conducted to assess United States (US) payer perspectives toward CGT reimbursement. Participants were recruited <i>via</i> third-party vendors to minimize bias. Data collection included Likert-scale ratings and open-ended inquiries regarding access, formulary processes, and reimbursement frameworks.</p><p><strong>Results: </strong>Twenty payer decision-makers were interviewed. While 17 viewed CGTs as among the most important medical innovations of our time, 18 agreed that the US healthcare system is not adequately prepared for broad CGT adoption. Top barriers to reimbursement include high upfront costs and long-term durability uncertainty. Preferred mitigation strategies include reinsurance/stop-loss and risk pools. Member portability and data tracking remain primary barriers to innovative payment models.</p><p><strong>Limitations: </strong>Sample size may not represent all US payers. Qualitative study findings identify trends and consensus only.</p><p><strong>Conclusions: </strong>Payers acknowledge the significant clinical promise of CGTs, but high upfront costs and long-term durability uncertainty continue to complicate coverage strategies and limit broader adoption. Ongoing evaluation of reimbursement frameworks, financing strategies, and emerging long-term evidence may help characterize how coverage and payment models evolve as the CGT landscape expands.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"2215-2227"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148865267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimated cost, resource use, and health benefits of an increased use of next-generation multi-target stool DNA test for colorectal cancer screening from an integrated delivery network perspective.","authors":"Michael Dore, Derek W Ebner, A Mark Fendrick, Chris Estes, Gustavus Aranda, Amber Coleman, Vahab Vahdat, Jordan J Karlitz, Tiago Rua, Frank van Hees, Paul J Limburg","doi":"10.1080/13696998.2026.2719374","DOIUrl":"https://doi.org/10.1080/13696998.2026.2719374","url":null,"abstract":"<p><strong>Aim: </strong>Multi-target stool DNA (mt-sDNA) and fecal immunochemical testing (FIT) are home-based options for colorectal cancer (CRC) screening. Next-generation mt-sDNA has enhanced sensitivity for CRC and advanced precancerous lesions compared with FIT and is not subject to the same capacity constraints as colonoscopy. This analysis evaluated the economic and clinical implications of increasing the proportional utilization of next-generation mt-sDNA.</p><p><strong>Methods: </strong>A budget impact model was developed from the validated CRC-AIM microsimulation model. The model simulated a cohort of 1 M average-risk, screen-eligible adults over a 3-year time horizon from an integrated delivery network perspective. The status quo scenario assumed an initial utilization of 20% next-generation mt-sDNA, 20% FIT, and 60% colonoscopy screening. In a hypothetical increased next-generation mt-sDNA scenario, its utilization expanded to 35% within 3 years, while FIT and colonoscopy utilization decreased to 15% and 50%, respectively. Test performance characteristics, real-world adherence, and cost inputs (i.e. screening test and programs, colonoscopy adverse events, CRC treatment) were derived from published literature. Multiple scenario analyses were conducted.</p><p><strong>Results: </strong>Among 1 M members, total costs in the status quo scenario were $1.058B and with increased next-generation mt-sDNA use were $1.046B, generating an estimated savings of $12.5 M (-$0.35 per member per month). Increasing next-generation mt-sDNA improved the CRC screening rate by 1.1%. Overall, 10,467 fewer screening colonoscopies and 1,912 more follow-up colonoscopies after a positive stool-based test were performed. An additional 17 CRCs were screening-detected, 11 fewer were clinically detected, and there was one less CRC-related death. Increased next-generation mt-sDNA utilization remained cost-saving with all scenario analyses.</p><p><strong>Conclusions: </strong>In this budget impact model, shifting a small proportion of current FIT and colonoscopy utilization to next-generation mt-sDNA for average-risk CRC screening is estimated to be cost-saving. Increasing the next-generation mt-sDNA utilization also improves the screening rate and clinical outcomes while optimizing availability of capacity-limited colonoscopy resources.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"2228-2240"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149110885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The ongoing challenge of <i>Clostridioides difficile</i> infection in Austria: economic evaluation of two recommended treatment pathways.","authors":"Evelyn Walter, Marco Voit, Gerald Eichhober, Gordon Spencer, Lei Wang, Vanessa Stadlbauer","doi":"10.1080/13696998.2026.2718661","DOIUrl":"10.1080/13696998.2026.2718661","url":null,"abstract":"<p><strong>Objectives: </strong>Clostridioides difficile (CD) is a major nosocomial pathogen causing severe and potentially life-threatening infections, particularly following disruption of gut microbiota. Transmission occurs <i>via</i> resilient spores through the fecal-oral route. While most infections originate in hospitals or long-term care facilities, 20-30% are community-acquired. In Austria, national surveillance data report 769 severe CDI cases in 2024, indicating a substantial disease burden. This analysis compares two treatment scenarios: (1) the pathway recommended by the Austrian Society of Gastroenterology and Hepatology (ÖGGH), which designates fidaxomicin as first-line therapy and reflects its reimbursement under the national reimbursement-code (positive list) as of December 2025, and (2) clinical practice prior to reimbursement, when the use of fidaxomicin was restricted by reimbursement constraints (reference pathway).</p><p><strong>Methods: </strong>A decision-tree model simulated CDI treatment. Patients could receive up to three successive therapies per episode and experience up to two recurrences. Treatment duration was fixed for 10 days. Inputs-patient characteristics, response rates, recurrence risk, utilities, CDI-related mortality, and costs (2025€)-were sourced from literature and validated by clinical experts. The model was evaluated over a lifetime horizon from the perspective of the Austrian healthcare system. Deterministic and probabilistic sensitivity-analyses tested robustness.</p><p><strong>Results: </strong>Average lifetime costs per patient were 4,026.86€for the ÖGGH pathway and 4,082.90€for the reference pathway, yielding incremental savings of -56.04€. Higher treatment costs (+234.29€) were offset by reduced downstream costs (-290.33€). The ÖGGH strategy improved outcomes, with 0.12 additional QALYs (7.01 vs. 6.89) and 0.20 life years gained (10.75 vs. 10.55), resulting in a dominant incremental cost-utility ratio (-478.25€/QALY).</p><p><strong>Conclusions: </strong>Fidaxomicin reimbursement is the dominant strategy and supports implementation of the ÖGGH guideline in Austria.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"2186-2200"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148794209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost‑effectiveness analysis of the mRNA‑1345 RSV vaccine for older adults in Italy.","authors":"Mariia Dronova, Camille Moyon, Lukasz Pyrek, Katherine Hicks, Ziyi Xiao, Filippo Rumi, Chiara de Waure, Stefan Scholz, Parinaz Ghaswalla","doi":"10.1080/13696998.2026.2746277","DOIUrl":"https://doi.org/10.1080/13696998.2026.2746277","url":null,"abstract":"<p><strong>Aims: </strong>To evaluate the potential public health impact and cost-effectiveness of vaccination using mRNA-1345 administered as a single dose compared with no vaccination in Italian high-risk adults aged 60-74 years and all adults aged ≥75 years.</p><p><strong>Methods: </strong>A static decision-analytic model was developed to project clinical and economic outcomes over a five-year time horizon, assuming 50% vaccination coverage among eligible adults. Economic outcomes were evaluated from the Italian National Health Service (Servizio Sanitario Nazionale, SSN) perspective. Model inputs were informed by the most recent Italian epidemiological, clinical, and economic evidence, supplemented by published international data when necessary. Deterministic, probabilistic, and scenario analyses were conducted to assess the impact of uncertainty in model inputs and assumptions on the study results.</p><p><strong>Results: </strong>Vaccination with mRNA-1345 in high-risk adults aged 60-74 years and all adults aged ≥75 years was projected to avert over 19,800 hospitalizations, 4,000 emergency department visits, 381,000 outpatient visits, 6,000 RSV-attributable deaths, and 212,000 antibiotic prescriptions compared with no vaccination over a five-year period. The total incremental cost of €1,143 million and the additional 47,477 QALYs gained resulted in an ICER of €24,078 per QALY gained, which was below the commonly referenced willingness-to-pay range of €33,000-40,000/QALY. Sensitivity analyses confirmed robustness of the analysis results.</p><p><strong>Limitations: </strong>Due to limited epidemiological evidence for Italy, selected epidemiological inputs were informed by studies conducted in other high-income countries. In addition, vaccine efficacy beyond the two-year clinical trial follow-up was projected to five years using nonlinear waning curves fitted to the observed trial data.</p><p><strong>Conclusions: </strong>Vaccination with mRNA-1345 is a cost-effective strategy for the prevention of RSV in high-risk adults aged 60-74 years and all adults ≥75 years in Italy, in comparison to no vaccination, and has the potential to provide substantial public health benefits.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"2552-2571"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment patterns, healthcare utilization, and healthcare costs in patients with newly diagnosed type 1 diabetes: a retrospective real-world study in Tianjin, China.","authors":"Wei Liu, Linong Ji, Yu Chen, Xiaohua Li, Wenjuan Li, Min Li, Minlu Zhang, Jun Tan, Ming Song","doi":"10.1080/13696998.2026.2738350","DOIUrl":"https://doi.org/10.1080/13696998.2026.2738350","url":null,"abstract":"<p><strong>Aims: </strong>Data on healthcare among people with type 1 diabetes (T1D) in mainland China are limited. This real-world study evaluated treatment patterns, healthcare resource utilization (HCRU) and healthcare costs among people with newly diagnosed T1D in Tianjin, China.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted using data from a medical records database. The objective was to evaluate clinical characteristics, treatment patterns, HCRU, and healthcare costs in people with newly diagnosed T1D between January 1, 2019 and December 31, 2023.</p><p><strong>Results: </strong>In total, 1396 people with newly diagnosed T1D were included (mean ± standard deviation age 30.6 ± 22.2 years; 38.8% aged <18 years [mean age 9 years]). At diagnosis, 70.3% required hospitalization or emergency care and 43.3% had diabetic ketoacidosis, with a higher prevalence in children and adolescents (65.7%). The three most common initial insulin regimens were insulin pump (30.4%), basal-bolus insulin (24.3%), and bolus insulin only (20.9%). During follow-up, the mean total all-cause HCRU was 14.32 clinical visits per person per year (PPPY) and the mean length of all-cause hospitalization was 14.14 days PPPY. Mean total all-cause healthcare costs were 28256.13 Chinese Yuan Renminbi (CNY) PPPY.</p><p><strong>Conclusions: </strong>People with T1D in Tianjin, China presented with severe conditions at diagnosis and had substantial ongoing HCRU and healthcare costs; actual costs may have been underestimated due to database limitations. These findings highlight the considerable clinical complexity and healthcare expenditure observed in individuals with T1D in China and emphasize the urgent need for effective strategies to improve T1D management and address the healthcare system burden.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"2464-2476"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149193757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The full value of mRNA seasonal influenza and endemic-stage COVID-19 combination vaccines: a taxonomy.","authors":"J P Sevilla, Joseph S Knee, Daria Burnes, Genevieve Meier, Jingyan Yang, Manuela Di Fusco, Tianyan Hu, David E Bloom","doi":"10.1080/13696998.2026.2638676","DOIUrl":"10.1080/13696998.2026.2638676","url":null,"abstract":"<p><strong>Aims: </strong>Seasonal influenza and COVID-19 pose significant ongoing threats to global health. Vaccination remains central to their prevention. Messenger RNA combination influenza and COVID-19 vaccines (mRNA combo vaccines) are in development. Payers will soon need to make value-for-money (VfM) assessments and coverage decisions regarding these vaccines. Value taxonomies play an important role in VfM assessments and coverage decisions. However, no taxonomy exists that captures the full value of mRNA combo vaccines. We aimed to construct a taxonomy of the full value, from a societal perspective, of mRNA combo vaccines in working-age (18-64 years) and older adults (65+ years).</p><p><strong>Methods: </strong>We (1) performed a targeted literature review (TLR) of existing value taxonomies and value attributes of COVID-19, influenza, other mRNA, and other combination vaccines; and (2) synthesized the value elements found in the TLR into a comprehensive taxonomy specific to mRNA combo vaccines.</p><p><strong>Results: </strong>Of 1851 identified studies, 57 contained relevant value elements. We constructed a taxonomy distinguishing narrow health-related from broader societal values, and traditional from novel values. Value elements in the taxonomy included improved health and reduced treatment costs; improved productivity; improved strain selection, raising vaccine efficacy; greater compliance with vaccine schedules, increasing uptake; improved patient and caregiver health and reduced treatment costs from such greater efficacy and uptake; reduced adverse events, anxiety and vaccination costs from reduced doses; process utilities from increased convenience; higher patient and provider acceptability; increased equity; and health-related R&D spillovers.</p><p><strong>Limitations: </strong>The TLR was non-systematic. We do not address potential redundancies or the relative importance of different values.</p><p><strong>Conclusions: </strong>Many value elements in the taxonomy are traditional narrow values and fit within a health payer perspective, but the taxonomy also captures broader societal values. This taxonomy can support more comprehensive valuations of mRNA combo vaccines in national vaccine recommendation and funding decisions.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"848-870"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147473866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma.","authors":"Toby A Eyre, Leyla Mohseninejad, Lianne Barnieh, Kaijun Wang, Yiran He, Keri Yang, Rhys Williams, Bijal D Shah","doi":"10.1080/13696998.2026.2696131","DOIUrl":"10.1080/13696998.2026.2696131","url":null,"abstract":"<p><strong>Objective: </strong>No head-to-head trials have compared the efficacy of zanubrutinib versus ibrutinib in relapsed/refractory mantle-cell lymphoma (R/R MCL).</p><p><strong>Methods: </strong>Following a systematic literature review, individual patient data from trials of zanubrutinib (<i>n</i> = 118) and aggregate data from a pooled analysis of ibrutinib trials (<i>n</i> = 370) were analyzed using an unanchored matching-adjusted indirect comparison (MAIC).</p><p><strong>Results: </strong>After matching selected covariates, statistically significant differences were observed with zanubrutinib versus ibrutinib for progression-free survival (hazard ratio [HR] = 0.63; 95% confidence interval [CI] 0.46-0.87, <i>p</i> = .0044) and overall survival (HR, 0.46; 95% CI 0.30-0.71, <i>p</i> = .0005).</p><p><strong>Conclusion: </strong>These MAIC analyses demonstrate that zanubrutinib may be more effective than ibrutinib at delaying disease progression and death in R/R MCL.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"29 1","pages":"1923-1932"},"PeriodicalIF":3.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148447575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}